Geneva, Oct. 9 -- International Clinical Trials Registry received information related to the study (ChiCTR2600133567) titled 'A Multimodal Artificial Intelligence Framework for the Diagnosis and Prognostic Evaluation of TFE3-Rearranged Renal Cell Carcinoma' on Sept. 29.
Study Type: Observational study
Study Design:
Sequential
Primary Sponsor: Ruijin Hospital, Shanghai Jiao Tong University School of Medicine
Condition:
TFE3 rearrangement-type renal cell carcinoma and other common subtypes of renal cell carcinoma
Recruitment Status: Not Recruiting
Phase: N/A
Date of First Enrollment: 2026-10-01
Target Sample Size: Group observing TFE3 rearrangement-type renal cell carcinoma and other common subtypes of renal cell carcinoma:300;...